DELTA-FLY-PHARMA
7.12.2022 07:12:34 CET | Business Wire | Press release
Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML).
Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval.
DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients’ enrollment plan soon.
Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families.
Company profile |
|
Company name |
Delta-Fly Pharma, Inc. [Tokyo:4598] |
Capital |
3352 million Japanese Yen |
Name and Title of Representative |
Kiyoshi Eshima, PhD, President |
Date of Incorporation |
December 6, 2010 |
Description of Business |
Research and development, manufacturing and marketing of pharmaceuticals |
Head Office |
37-5, Nishikino, Miyajima, Kawauchi-cho, Tokushima 771-0116, Japan |
Branch Office |
Tokyo, Beijing, Vancouver |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221206006153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe's Largest Halloween Festival Marks 40 Years in the Birthplace of Halloween27.10.2026 13:37:00 CET | Press release
As Derry Halloween celebrates 40 years, festivals across the island of Ireland bring more than 2,000 years of Halloween tradition to life Rooted in the ancient Celtic festival of Samhain, which marked the end of the harvest season and the beginning of winter more than 2,000 years ago, Halloween can trace its origins to Ireland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020759137/en/ Derry Halloween, Co. Derry~Londonderry This year, the story comes full circle as Derry Halloween, Europe's oldest and largest Halloween festival, celebrates its 40th anniversary, leading a programme of events across the island that blend history, storytelling, music, food and spectacle. Derry Halloween began organically as a community celebration in 1985, when a Halloween fancy-dress party in a local pub was evacuated during a security alert at the height of the Troubles, sending revellers onto the streets and sparking a tradition that wo
Effort Inflation Puts Brand Loyalty at Risk, Netcracker/CSG Research Finds27.10.2026 13:30:00 CET | Press release
2027 State of the Customer Experience Report shows customers turn to third-party AI for help, while effective automation and human support strengthen loyalty Netcracker/CSG® today released the 2027 State of the Customer Experience Report, which finds that “Effort Inflation,” the growing time, steps, and mental effort customers must use to engage with brands, is damaging trust and loyalty. The findings show that customers will stay with brands that make touchpoints faster and easier, ensure continuity across channels, and preserve access to human support when needed. One consequence of Effort Inflation is the rise of a “shadow customer experience” layer, where customers turn to third-party AI assistants and personal agents to navigate brand interactions, pushing critical touchpoints out of the brand’s control. As more support journeys shift outside owned channels, brands risk losing visibility, context, and opportunities to build trust. This trend reinforces the need for connected, effo
AHS Properties to Launch USD 1.3 Billion AHS Twin Towers, a Grade A Commercial Office Building on Sheikh Zayed Road27.10.2026 13:17:00 CET | Press release
AHS Properties is set to launch AHS Twin Towers, its new commercial development on Sheikh Zayed Road, following the AED 1.1 billion acquisition of Shangri-La Dubai. The property will undergo a major transformation into a Grade A commercial destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027110920/en/ Abbas Sajwani, Founder and CEO of AHS Properties (Photo: AETOSWire) Positioned on one of Dubai’s most prominent commercial corridors, AHS Twin Towers will introduce a new architectural identity for the property. The project has been designed by Gensler, an internationally recognised architecture and design firm, with interiors by AHS Atelier, the company’s in-house design studio, bringing a bespoke approach to materiality, detailing and craftsmanship throughout the development. AHS Twin Towers will comprise ground floor plus 50. The development will offer flexible Grade A office environments supported by an integr
JERA Signs a Binding Heads of Agreement with AM Green for Long-Term Supply of Green Ammonia for Maritime Decarbonization27.10.2026 13:11:00 CET | Press release
JERA Co., Inc. (JERA) and AM Green Ammonia (India) Private Limited (AM Green) today jointly announced that it has entered into a Binding Heads of Agreement ("HoA") with AM Green regarding the long-term supply of green ammonia produced in India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027189014/en/ JERA and AM Green have agreed upon supply of approximately 70,000 tonnes of green ammonia annually over five years, with potential extension of term for additional supply. The green ammonia is intended to be supplied through receiving, storage and distribution facilities being developed adjacent to JERA's Hekinan Thermal Power Station in Aichi Prefecture, Japan. Green ammonia would primarily be supplied to a business venture jointly to be established by Kawasaki Kisen Kaisha, Ltd. and Nippon Yusen Kabushiki Kaisha, which plans to utilize an ammonia bunkering vessel to supply fuel to ammonia-fueled car carriers. This marks
Pythia Labs Launches with AI-Designed Antibodies for Hard-to-Drug Targets27.10.2026 13:00:00 CET | Press release
Biotech startup demonstrates rapid AI design of full-length human antibodies that inhibit or activate GPCRs, with key properties required for therapeutic development Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, today announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027891477/en/ Pythia's AI technology platform can design antibodies against traditionally challenging targets such as multi-pass membrane proteins. Pythia’s technology is built to create antibodies against targets that have challenged conventional discovery, including multi-pass membrane proteins such as G protein-coupled receptors (GPCRs). Generating antibodies that activate these receptors has been a longstanding goal in antibody discovery. Pythia-1 reasons jointly ov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom